The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...

Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.8% higher at $24.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Gilead Sciences and Arcus Biosciences said they’ve expanded their three-year-old collaboration. An equity stake in Arcus, board seat for Gilead’s commercial chief and a streamlined immuno-oncology ...

The market expects Arcus Biosciences, Inc. (RCUS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, is ...